Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
In vivo xenografts of human melanoma cancer cells treated with TekdeltaFc and LDM CTX. Relative tumor growth for each treatment group: Control, TekdeltaFc, low-dose metronomic cyclophosphamide (LDM CTX), and combination for two weeks. There were no statistically significant differences in tumor growth between treatment groups at any time points ().
We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at email@example.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.